Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium PR Newswire VANCOUVER, BC, Jan. 22, 2025 USA News Group News Commentary Issued on behalf of Oncolytics...
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS PR Newswire BOSTON and SAN DIEGO and...
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024 FN Media Group Presents USA News Group News Commentary PR Newswire VANCOUVER, BC, Jan. 10, 2022...
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024 FN Media Group Presents USA News Group News Commentary PR Newswire VANCOUVER, BC, Jan. 10, 2022...
CALGARY, Alberta and SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...
- Increased PD-L1 expression correlates with clinical response when pelareorep is combined with a proteasome inhibitor - - Data continue to recommend pelareorep as a standardized backbone for...
CALGARY, Alberta and SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...
CALGARY, Alberta and SAN DIEGO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...
CALGARY, Alberta and SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.12 | -10.0840336134 | 1.19 | 1.19 | 1.03 | 150187 | 1.07018834 | CS |
| 4 | -0.3 | -21.897810219 | 1.37 | 1.4 | 1.03 | 144267 | 1.19058685 | CS |
| 12 | -0.43 | -28.6666666667 | 1.5 | 1.6 | 1.02 | 138524 | 1.25871401 | CS |
| 26 | -0.4 | -27.2108843537 | 1.47 | 2.08 | 1.02 | 117360 | 1.40221775 | CS |
| 52 | -0.59 | -35.5421686747 | 1.66 | 2.08 | 1.02 | 87371 | 1.41721049 | CS |
| 156 | -1.21 | -53.0701754386 | 2.28 | 4.49 | 1.02 | 81690 | 2.15109686 | CS |
| 260 | -2.29 | -68.1547619048 | 3.36 | 6.06 | 1.02 | 119715 | 2.7923568 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
